Progesterone Receptor Antagonists and the Endometrial Antiproliferative Effect

 

 Buy Article Permissions and Reprints

ABSTRACT

Progesterone receptors (PR) mediate multiple aspects of female reproduction and are important targets for reagents that can modulate progesterone-dependent events. Many such reagents have been developed, and they range from full PR antagonists (PAs) to compounds with mixed agonist/antagonist actions, currently known as selective progesterone receptor modulators (SPRMs). In women and nonhuman primates, many PR antagonists suppress estrogen-dependent mitotic activity in the endometrial glands as well as block progestational development of the endometrium. These latter effects are tissue- and species-specific, are most dramatic in women and nonhuman primates, and are referred to as endometrial antiproliferative effects. Recent evidence suggests that the endometrial androgen receptor plays an important role in these effects. For example, endometrial androgen receptors are increased by treatment with PAs, and combination treatment with estrogen, a PA, and an antiandrogen (flutamide) prevents the endometrial antiproliferative effect. Various PR modulators have great promise as gynecological therapeutics, but additional research is needed to improve our understanding of their endometrial effects.

REFERENCES

• 1 Spitz I M, Robbins A. Mechanism of action and clinical effects of antiprogestins on the non- pregnant uterus.  Hum Reprod Update. 1998;  4 584-593
  CrossrefPubMedGoogle Scholar
• 2 Leonhardt S A, Edwards D P. Mechanism of action of progesterone antagonists.  Exp Biol Med (Maywood). 2002;  227 969-980
  PubMedGoogle Scholar
• 3 Cadepond F, Ulmann A, Baulieu E E. RU486 (mifepristone): mechanisms of action and clinical uses.  Annu Rev Med. 1997;  48 129-156
  CrossrefPubMedGoogle Scholar
• 4 Bennink H. The Jerusalem declaration on progesterone receptor modulators.  Steroids. 2000;  65 839
  CrossrefPubMedGoogle Scholar
• 5 Philibert D. RU 38486: an original multifaceted antihormone in vivo. In: Agarwal MK Adrenal Steroid Antagonism Berlin, Germany; Gruyter 1984: 77-101
  Google Scholar
• 6 Slayden O D, Chwalisz K, Brenner M R. Reversible suppression of menstruation with progesterone antagonists in rhesus macaques.  Hum Reprod. 2001;  16 1562-1574
  CrossrefPubMedGoogle Scholar
• 7 Gainer E, Ulmann A. Pharmacologic properties of CDB (VA)-2914.  Steroids. 2003;  68 1005-1011
  CrossrefPubMedGoogle Scholar
• 8 Elger W, Bartley J, Schneider B et al.. Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity.  Steroids. 2000;  65 713-723
  CrossrefPubMedGoogle Scholar
• 9 Chwalisz K, Brenner R M, Fuhrmann U, Hess-Stumpp H, Elger W. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators (PRMs) on the endometrium.  Steroids. 2000;  65 741-751
  CrossrefPubMedGoogle Scholar
• 10 Wolf J P, Hsiu J G, Anderson T L et al.. Noncompetitive antiestrogenic effect of RU 486 in blocking the estrogen- stimulated luteinizing hormone surge and the proliferative action of estradiol on endometrium in castrate monkeys.  Fertil Steril. 1989;  52 1055-1060
  PubMedGoogle Scholar
• 11 Slayden O D, Zelinski-Wooten M B, Chwalisz K, Stouffer R L, Brenner M R. Chronic treatment of cycling rhesus monkeys with low doses of the antiprogestin ZK 137 316: morphometric assessment of the uterus and oviduct.  Hum Reprod. 1998;  13 269-277
  CrossrefPubMedGoogle Scholar
• 12 Grow D R, Williams R F, Hsiu J G, Hodgen D G. Antiprogestin and/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: a 1-year primate study.  J Clin Endocrinol Metab. 1996;  81 1933-1939
  CrossrefPubMedGoogle Scholar
• 13 Grow D R, Reece M T, Hsiu J G et al.. Chronic antiprogestin therapy produces a stable atrophic endometrium with decreased fibroblast growth factor: a 1-year primate study on contraception and amenorrhea.  Fertil Steril. 1998;  69 936-943
  CrossrefPubMedGoogle Scholar
• 14 Cameron S T, Critchley H OD, Thong K J et al.. Effects of daily low dose mifepristone on endometrial maturation and proliferation.  Hum Reprod. 1996;  11 2518-2526
  PubMedGoogle Scholar
• 15 Brown A, Cheng L, Lin S, Baird T D. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days.  J Clin Endocrinol Metab. 2002;  87 63-70
  CrossrefPubMedGoogle Scholar
• 16 Zelinski-Wooten M B, Chwalisz K, Iliff S A et al.. A chronic, low dose regimen of the antiprogestin ZK 137 316 prevents pregnancy in rhesus monkeys.  Hum Reprod. 1998;  13 2132-2138
  CrossrefPubMedGoogle Scholar
• 17 Borman S M, Schwinof K M, Niemeyer C et al.. Low-dose antiprogestin treatment prevents pregnancy in rhesus monkeys and is reversible after 1 year of treatment.  Hum Reprod. 2003;  18 69-76
  CrossrefPubMedGoogle Scholar
• 18 Demanno B, Elger W, Garg R et al.. Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy.  Steroids. 2003;  68 1019-1032
  CrossrefPubMedGoogle Scholar
• 19 Chwalisz K, Larsen L, McCrary K, Edmonds A. Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata.  J Soc Gynecol Investig. 2004;  11(suppl 2) 320-321
  PubMedGoogle Scholar
• 20 Bardon S, Vignon F, Montcourrier P, Rochefort H. Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells.  Cancer Res. 1987;  47 1441-1448
  PubMedGoogle Scholar
• 21 Murphy A A, Zhou M H, Malkapuram S et al.. RU486-induced growth inhibition of human endometrial cells.  Fertil Steril. 2000;  74 1014-1019
  CrossrefPubMedGoogle Scholar
• 22 Parthasarathy S, Morales A J, Murphy A A. Antioxidant: a new role for RU-486 and related compounds.  J Clin Invest. 1994;  94 1990-1995
  PubMedGoogle Scholar
• 23 Han S, Sidell N. RU486-Induced growth inhibition of human endometrial cells involves the nuclear factor-kappaB signaling pathway.  J Clin Endocrinol Metab. 2003;  88 713-719
  CrossrefPubMedGoogle Scholar
• 24 Chwalisz K, Stöckemann K, Fritzemeier K-H. Fuhrmann U. Modulation of oestrogenic effects by progesterone antagonists in the rat uterus.  Hum Reprod Update. 1998;  4 570-583
  CrossrefPubMedGoogle Scholar
• 25 Grody M H, Lampe E H, Masters H W. Estrogen-androgen substitution therapy in the aged female.  Obstet Gynecol. 1953;  2 36-45
  PubMedGoogle Scholar
• 26 Okon M A, Laird S M, Tuckerman E M, Li T-C. Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function.  Fertil Steril. 1998;  69 682-690
  CrossrefPubMedGoogle Scholar
• 27 Rose G L, Dowsett M, Mudge J E, White J O, Jeffcoate L S. The inhibitory effects of danazol, danazol metabolites, gestrinone, and testosterone on the growth of human endometrial cells in vitro.  Fertil Steril. 1988;  49 224-228
  PubMedGoogle Scholar
• 28 Tuckerman E M, Okon M A, Li T-C, Laird M S. Do androgens have a direct effect on endometrial function? An in vitro study.  Fertil Steril. 2000;  74 771-779
  CrossrefPubMedGoogle Scholar
• 29 Critchley H, Wang H, Jones R et al.. Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery.  Hum Reprod. 1998;  13 1218-1224
  CrossrefPubMedGoogle Scholar
• 30 Critchley H OD, Brenner R M, Henderson T A et al.. Estrogen receptor beta, but not estrogen receptor alpha, is present in the vascular endothelium of the human and nonhuman primate endometrium.  J Clin Endocrinol Metab. 2001;  86 1370-1378
  CrossrefPubMedGoogle Scholar
• 31 Cameron S T, Critchley H OD, Buckley C H, Kelly R W, Baird T D. Effect of two antiprogestins (mifpristone and onapristone) on endometrial factors of potential importance for implantation.  Fertil Steril. 1997;  67 1046-1053
  CrossrefPubMedGoogle Scholar
• 32 Slayden O D, Nayak N R, Burton K A et al.. Progesterone antagonists increase androgen receptor expression in the rhesus macaque and human endometrium.  J Clin Endocrinol Metab. 2001;  86 2668-2679
  CrossrefPubMedGoogle Scholar
• 33 Narvekar N, Cameron S, Critchley H et al.. Low-dose mifepristone inhibits endometrial proliferation and up-regulates androgen receptor.  J Clin Endocrinol Metab. 2004;  89 2491-2497
  CrossrefPubMedGoogle Scholar
• 34 Slayden O D, Brenner M R. Flutamide counteracts the antiproliferative effects of antiprogestins in the primate endometrium.  J Clin Endocrinol Metab. 2003;  88 946-949
  CrossrefPubMedGoogle Scholar
• 35 Cooke P S, Buchanan D L, Young P et al.. Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium.  Proc Natl Acad Sci USA. 1997;  94 6535-6540
  CrossrefPubMedGoogle Scholar
• 36 McClellan M C, Rankin S, West N B, Brenner M R. Estrogen receptors, progestin receptors and DNA synthesis in the macaque endometrium during the luteal-follicular transition.  J Steroid Biochem Mol Biol. 1990;  37 631-641
  CrossrefPubMedGoogle Scholar
• 37 Ikonen T, Palvimo J J, Kallio P J, Reinikainen P, Janne A O. Stimulation of androgen-regulated transaction by modulators of protein phosphorylation.  Endocrinology. 1994;  135 1359-1366
  CrossrefPubMedGoogle Scholar
• 38 Apparao K B, Lovely L P, Gui Y, Lininger R A, Lessey A B. Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome.  Biol Reprod. 2002;  66 297-304
  CrossrefPubMedGoogle Scholar
• 39 Ajossa S, Guerriero S, Paoletti A M, Orru M, Melis B G. The antiandrogenic effect of flutamide improves uterine perfusion in women with polycystic ovary syndrome.  Fertil Steril. 2002;  77 1136-1140
  CrossrefPubMedGoogle Scholar
• 40 de Ziegler D, Bessis R, Frydman R. Vascular resistance of uterine arteries: physiological effects of estradiol and progesterone.  Fertil Steril. 1991;  55 775-779
  PubMedGoogle Scholar
• 41 Reinsch R C, Murphy A A, Morales A J, Yen S SC. The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study.  Am J Obstet Gynecol. 1994;  170 1623-1628
  PubMedGoogle Scholar
• 42 Charmandari E, Calis K A, Keil M F et al.. Flutamide decreases cortisol clearance in patients with congenital adrenal hyperplasia.  J Clin Endocrinol Metab. 2002;  87 3197-3200
  CrossrefPubMedGoogle Scholar
• 43 Baird D T, Brown A, Critchley H O et al.. Effect of long-term treatment with low-dose mifepristone on the endometrium.  Hum Reprod. 2003;  18 61-68
  CrossrefPubMedGoogle Scholar
• 44 Eisinger S, Meldrum S, Fiscella K, le Roux H, Guzick D. Low-dose mifepristone for uterine leiomyomata.  Obstet Gynecol. 2003;  101 243-250
  CrossrefPubMedGoogle Scholar
• 45 Croxatto H B, Kovács L, Massai R et al.. Effects of long-term low-dose mifepristone on reproductive function in women.  Hum Reprod. 1998;  13 793-798
  CrossrefPubMedGoogle Scholar
• 46 Murphy A, Kettel L, Morales A et al.. Endometrial effects of long-term low-dose administration of RU486.  Fertil Steril. 1995;  63 761-766
  PubMedGoogle Scholar
• 47 Newfield R, Spitz I, Isacson C, New M. Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia.  Clin Endocrinol (Oxf). 2001;  54 399-404
  CrossrefPubMedGoogle Scholar
• 48 Bamberger A M, Milde-Langosch K, Loning T, Bamberger M C. The glucocorticoid receptor is specifically expressed in the stromal compartment of the human endometrium.  J Clin Endocrinol Metab. 2001;  86 5071-5074
  CrossrefPubMedGoogle Scholar
• 49 Henderson T A, Saunders P T, Moffett-King A, Groome N P, Critchley O H. Steroid receptor expression in uterine natural killer cells.  J Clin Endocrinol Metab. 2003;  88 440-449
  Google Scholar
• 50 Brenner R M, Slayden O D, Rodgers W H et al.. Immunocytochemical assessment of mitotic activity with an antibody to phosphorylated histone H3 in the macaque and human endometrium.  Hum Reprod. 2003;  18 1185-1193
  CrossrefPubMedGoogle Scholar

Robert M BrennerPh.D. 

Division of Reproductive Sciences, Oregon National Primate Research Center, Oregon Health & Sciences University

505 NW 185th Ave, Beaverton, OR 97006

Email: brennerr@ohsu.edu